Forgot Password

Autism cord blood trials

Autologous cord blood stem cells for autism

The purpose of this trial is to determine the effect of umbilical cord blood infusion in treating children with autism. The trial is being undertaken by the Sutter Institute for Medical Research in Sacramento California and expects to recruit 30 children from 2 to 7 years of age that have been diagnosed with autism. Participants will be randomly divided into two groups. One group will receive an infusion of their own umbilical cord blood (initial experimental group). The other group will receive a placebo infusion of saline, but then after 24 weeks, they will receive their own umbilical cord blood. The initial experimental group will receive a placebo injection at 24 weeks. Both groups will be tested at 24 weeks after initial infusion, and then again after another 24 weeks. The participants, their carers and their doctors will not know which group they have been assigned to. In the follow-up period each child will be monitored for complications and changes in their clinical condition. 

Location: California, USA
Trial design: Efficacy study
Status: Open – recruiting
Find out more

Autologous umbilical cord blood infusion for children with autism spectrum disorder 

This study is being undertaken at the Duke University Medical Centre. The study is a prospective phase 1 single-centre trial designed to determine the safety of a single intravenous infusion of autologous umbilical cord blood in children with Autism Spectrum Disorder (ASD). The trial aims to recruit 20 children between 24 and 72 months of age with a diagnosis of ASD with stored autologous (their own) cord blood. Participants in the study will receive an infusion of their own cord blood, with follow up assessments at 6 and 12 months after the infusion.

Location: North Carolina, USA
Trial design: Safety and efficacy    
Status: Active – not yet recruiting 
Find out more